Another dual PI3K/mTOR inhibitor, PI-103, which is known to have monotherapy efficacy in glioma [5] was recently shown to specifically reduce tumor volumes in combination with NSC-delivered s-trail in an orthotopic intracranial xenograft model [15]. This evidence concerns the gene MTOR and central nervous system cancer.